AstraZeneca AB v Pharmacor Pty Ltd

AstraZeneca AB v Pharmacor Pty Ltd [2026] FCA 88 is a Federal Court interlocutory injunction decision about a planned generic launch of dapagliflozin products in Australia. The case sits in patent law and launch control, not in ordinary consumer law or advertising law.

On the available judgment text, AstraZeneca sought urgent orders to stop Pharmacor from selling, supplying, offering, or taking PBS-related steps for dapagliflozin products before the patent expired or the dispute was finally determined. The court granted the interlocutory injunction with minor changes and made additional orders requiring prompt regulator notifications and withdrawal steps in relation to PBS listing activity.

The extract shows that infringement was not in factual dispute on the interlocutory material. The main contest was whether Pharmacor's invalidity case, especially on novelty, was strong enough to qualify or negate AstraZeneca's prima facie case. The reasons reproduced in the extract spend substantial time on novelty principles where prior art discloses a broad class of chemical compounds by generic formula.

Businesses should read this as a launch-risk case. It shows how quickly a court can intervene before trial where patent rights, regulatory timing and market entry are closely connected.

AstraZeneca AB was the registered proprietor of Australian Patent No. 2003237886 for “C-aryl glucoside SGLT2 inhibitors and method”, a patent relating to dapagliflozin. The judgment says dapagliflozin is used in the treatment of diabetes, chronic kidney disease and heart failure. The patent had a priority date of 20 May 2002 and was due to expire on 22 October 2027. AstraZeneca AB had acquired the patent from Bristol-Myers Squibb Co, and AstraZeneca Pty Ltd, its subsidiary, marketed dapagliflozin tablets in Australia under the brand FORXIGA as well as certain combination products containing dapagliflozin.

Pharmacor Pty Limited was entered on the ARTG on 14 November 2025 as sponsor of four dapagliflozin products. After a letter of demand, Pharmacor told AstraZeneca on 3 December 2025 that it expected two of those products would be listed on the PBS with effect from 1 April 2026. That meant the dispute was not theoretical. It concerned a near-term generic launch pathway in a regulated market before patent expiry.

AstraZeneca commenced proceedings on 17 December 2025 and sought an interlocutory injunction. The hearing took place on an expedited basis on 6 February 2026 because PBS timing created a hard commercial deadline. The extract says that if the injunction were granted, Pharmacor would need to take steps to withdraw its PBS listing activity, including changing the forecast effective date or withdrawing the application, and the cut-off date for doing so was 18 February 2026.

The parties also narrowed the interlocutory fight. The extract says there was no factual debate on the pleadings or evidence that the Pharmacor products fell within claims 1 to 3 of the patent and that Pharmacor would provide instructions to use the products in accordance with claim 16. At the hearing, it was common ground that the interlocutory application should focus on claims 1 and 2 only. Pharmacor's answer to AstraZeneca's infringement case on those claims was asserted invalidity.

That invalidity case relied heavily on an earlier Bristol-Myers Squibb patent application, WO 01/27128, published on 19 April 2001. According to the extract, that earlier document disclosed a broad class of C-aryl glucoside compounds by generic formula. Expert evidence referred to in the extract said the relevant formulae encompassed an immeasurably large number of potential compounds, comfortably exceeding millions of distinct combinations. Dapagliflozin was not one of the 80 compounds specifically identified in the examples in that earlier document, nor one of the specific compounds identified in its claims.

So the commercial and legal story was this: a patent owner with an established Australian product position moved urgently to stop a generic entrant that had ARTG registrations and expected PBS listing. The generic entrant did not, on the interlocutory material, deny that its products fell within the patent claims. Instead, it argued that the patent claims should not be treated as strong enough to support interim relief because they were invalid.

The immediate issue was whether the court should grant an interlocutory injunction restraining Pharmacor from exploiting its dapagliflozin products in Australia before trial. The extract states the familiar framework in practical terms: AstraZeneca needed to establish a prima facie case, and the court also had to consider the balance of convenience.

Because infringement was not in factual dispute on the interlocutory material, the pressure point was the strength of Pharmacor's invalidity case. Pharmacor argued lack of novelty, lack of inventive step and lack of manner of manufacture. The available reasons focus mainly on novelty and on how Australian law approaches prior disclosures of broad classes of chemical compounds.

The extract records the court's discussion of established authority that a prior disclosure does not automatically anticipate a later claim just because the earlier document describes a broad class that theoretically includes the later compound. The question is what the earlier document clearly and unmistakably disclosed to the skilled reader. The court reproduced and adopted passages explaining that there is an important difference between a broad disclosure that encompasses a later compound and a disclosure that actually teaches or directs the skilled addressee to that compound for novelty purposes.

Put simply, the novelty issue was not solved by saying dapagliflozin sat somewhere inside a very large earlier formula. The court had to ask whether the earlier document planted its flag at the precise destination, or whether it merely described a huge field of possibilities without clearly directing the skilled reader to the claimed compound.

Downes J granted the interlocutory injunction sought by AstraZeneca, with minor changes. The orders restrained Pharmacor, until the earlier of final determination, expiry of the patent, or further order, from selling, supplying or otherwise disposing of any of the Pharmacor products in Australia, offering to do so, causing any of the products to be listed on the PBS on a date before expiry or revocation of the patent, authorising another person to do those acts, and procuring or inducing or joining in a common design with another person to do those acts.

The court also made practical compliance orders tied to the PBS process. Pharmacor had to notify the Department of Health, Disability and Ageing and the Minister for Health, Disability and Ageing of the grant of the interlocutory injunction and its terms, and notify them that, for the purpose of seeking PBS listing effective on 1 April 2026, Pharmacor was no longer able to continue to provide the assurance or guarantee of supply it had given. Pharmacor also had to take reasonable steps to withdraw any PBS listing applications. Costs of the interlocutory application were reserved.

The extract also records undertakings given by AstraZeneca, including the usual undertaking as to damages. Additional undertakings addressed notice if another person intended to exploit a dapagliflozin product before patent expiry, diligent prosecution of interlocutory relief against such a person, and restrictions on causing PBS listing of a dapagliflozin product that would move the Forxiga product from the F1 formulary to the F2 formulary while Pharmacor remained restrained. There was also an undertaking not to exploit an authorised generic containing dapagliflozin while the restraint remained in place, and an undertaking to prosecute the claim for final relief expeditiously.

On the available text, the operative result is clear even though the full reasons are not reproduced. AstraZeneca established a prima facie case, infringement was not in dispute on the interlocutory material, and the court granted urgent relief after considering the invalidity arguments and the balance of convenience.

The first practical point is classification. This is a patent interlocutory injunction case, not a misleading or deceptive conduct case. If you are looking for guidance on advertising claims, website statements or section 18 of the Australian Consumer Law, this decision does not appear to provide that on the available text. Its real value is in showing how launch plans can be interrupted before trial when patent rights and regulatory milestones overlap.

The second point is that launch risk starts before first sale. The orders extended beyond actual sales and supply. They also covered offers to sell or supply, PBS listing steps, authorisation of others, and conduct that procured or induced those acts. Businesses in regulated sectors should map the whole launch chain, including listing applications, supply assurances, distributor instructions and internal approvals.

The third point is that an invalidity challenge may not be enough to keep a launch alive at the interlocutory stage. Pharmacor argued lack of novelty, inventive step and manner of manufacture. But on the available text, the court still found a prima facie case and granted temporary restraint. Businesses should therefore ask not only whether they have an arguable final defence, but whether that defence is likely to be strong enough to resist urgent interim relief.

The fourth point is operational readiness. The orders required immediate notifications to government decision-makers and reasonable steps to withdraw PBS applications. That is a reminder that legal disputes can trigger same-day or next-day operational tasks. Product, regulatory and commercial teams should know in advance who will communicate with authorities, who will pause launch activity, and what commitments may need to be revised if an injunction is granted.

Although this case arises in pharmaceuticals, the operational discipline applies more broadly. Before launch, identify the documents and conduct that could become relevant if another party seeks urgent relief. In this case, ARTG status, PBS listing expectations, supply assurances and the intended use instructions for the products all mattered to the shape and urgency of the dispute.

For businesses, that means reviewing not only the product itself but also the surrounding launch materials and commitments. Ask whether your product falls within another party's rights, whether your instructions or intended use align with a claimed use, whether any regulator application assumes uninterrupted supply, and whether your commercial timetable leaves room to respond to urgent court action.

It is also worth separating final merits questions from interim risk questions. A business may believe it has a serious challenge to the other side's rights, but still face an injunction if the court considers the claimant has shown a prima facie case and the balance of convenience favours preserving the status quo. That is especially true where launch timing could create immediate market effects or require rapid changes to government listing processes.

In practical terms, launch teams should have a legal sign-off gate before key external steps are taken. They should also have a contingency plan covering who will stop supply, who will contact regulators, what public or customer communications may be needed, and how evidence will be preserved if the dispute moves quickly.

The judgment is dated 16 February 2026. The hearing took place on 6 February 2026. The proceedings were commenced on 17 December 2025 after Pharmacor had been entered on the ARTG on 14 November 2025 and had informed AstraZeneca on 3 December 2025 of expected PBS listing for two products from 1 April 2026. The patent priority date was 20 May 2002 and the patent expiry date was 22 October 2027.

The available text is sufficient to explain the commercial setting, the interlocutory issue and the orders made. However, the reasons are truncated. The full judgment should be checked for the complete treatment of inventive step, manner of manufacture and balance of convenience, and to confirm whether section 18 of the Australian Consumer Law had any substantive role beyond appearing in the catchwords.